These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12917 related articles for article (PubMed ID: 10451027)
1. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells. Nam SM; Kim HS; Ahn WS; Park YS Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027 [TBL] [Abstract][Full Text] [Related]
2. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130 [TBL] [Abstract][Full Text] [Related]
3. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394 [TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Lopes de Menezes DE; Pilarski LM; Allen TM Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662 [TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies. Ohta S; Igarashi S; Honda A; Sato S; Hanai N Anticancer Res; 1993; 13(2):331-6. PubMed ID: 8517645 [TBL] [Abstract][Full Text] [Related]
8. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782 [TBL] [Abstract][Full Text] [Related]
9. Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. Ahmad I; Allen TM Cancer Res; 1992 Sep; 52(17):4817-20. PubMed ID: 1511445 [TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Gupta B; Torchilin VP Cancer Immunol Immunother; 2007 Aug; 56(8):1215-23. PubMed ID: 17219149 [TBL] [Abstract][Full Text] [Related]
11. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599 [TBL] [Abstract][Full Text] [Related]
12. [In vitro and in vivo targeting therapy of immunoliposomes against human gastric cancer]. Xu L; Zhang XY; Zhang SY Zhonghua Yi Xue Za Zhi; 1994 Feb; 74(2):83-6, 126. PubMed ID: 8069726 [TBL] [Abstract][Full Text] [Related]
13. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Sakakibara T; Chen FA; Kida H; Kunieda K; Cuenca RE; Martin FJ; Bankert RB Cancer Res; 1996 Aug; 56(16):3743-6. PubMed ID: 8706018 [TBL] [Abstract][Full Text] [Related]
14. [Study on third-type immunoliposomes loaded drugs and the targeting in vitro and in vivo]. Hou XP; Zhang YF; Xie SS; Hu X Yao Xue Xue Bao; 2001 Jul; 36(7):539-42. PubMed ID: 12585089 [TBL] [Abstract][Full Text] [Related]
15. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Allen TM; Mumbengegwi DR; Charrois GJ Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261 [TBL] [Abstract][Full Text] [Related]
16. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319 [TBL] [Abstract][Full Text] [Related]
17. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Williams SS; Alosco TR; Mayhew E; Lasic DD; Martin FJ; Bankert RB Cancer Res; 1993 Sep; 53(17):3964-7. PubMed ID: 8358724 [TBL] [Abstract][Full Text] [Related]
18. Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro. Moradpour D; Compagnon B; Wilson BE; Nicolau C; Wands JR Hepatology; 1995 Nov; 22(5):1527-37. PubMed ID: 7590672 [TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643 [TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]